Year: 2022

Tower Crane Rental Market Size [2022-2029] | Industry Share, Growth, Price and Trends Forecast Report

Written by Customer Service on December 13, 2022. Posted in Mergers And Acquisitions.

Tower Crane Rental Market Enter to a Period of Dramatic Expansion as of Increased Investment in Residential & Commercial Construction Pune, India, Dec. 12, 2022 (GLOBE NEWSWIRE) — The global tower crane rental market size expected to witness significant growth during the forecast period suggests Fortune Business Insights™ in its report, titled “Tower Crane Rental Market, 2021-2028”. The demand for rental construction equipment up surged due to shift from traditional to automated equipment as consumers are retro filling and renovating the old technology. Key Industry DevelopmentsFebruary 2020: Scotland based company, Highsparks TCS Ltd announced its acquisition by Uperio Group via its subsidiary Skyline Arcomet Ltd.Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/tower-crane-rental-market-104765Drivers...

Canoe EIT Income Fund Announces 2022 Annual Redemption Price

Written by Customer Service on December 13, 2022. Posted in Public Companies.

CALGARY, Alberta, Dec. 12, 2022 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (“Canoe” or the “Fund”)(TSX – EIT.UN) today announced that units accepted for the 2022 voluntary cash redemption will be redeemed at a rounded price of $13.36 per unit in Canadian dollars. This price is equal to 95% of the average net asset value per unit based on the three business days preceding the redemption date of December 9, 2022, less direct costs. Payment of the redemption proceeds will be made on or before January 4, 2023. About Canoe EIT Income FundCanoe EIT Income Fund is one of Canada’s largest closed-end investment funds, designed to maximize monthly distributions and capital appreciation by investing in a broadly diversified portfolio of high quality securities. The Fund is listed on the TSX under the symbols EIT.UN, EIT.PR.A and EIT.PR.B,...

AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

Written by Customer Service on December 13, 2022. Posted in Public Companies.

VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the results of its 2022 Annual Meeting of Stockholders, which was held virtually on December 12, 2022 (United States) (being December 13, 2022 in Australia). Election of Directors: All five directors named in the Company’s proxy statement dated October 19, 2022 (Proxy Statement) were elected or re-elected, as applicable, to serve on the Company’s Board of Directors: Louis Panaccio, Chair; James Corbett, Executive Director and CEO; Professor Suzanne Crowe, Director; Jeremy Curnock Cook, Director; and Jan Stern Reed, Director. Appointment...

NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting

Written by Customer Service on December 13, 2022. Posted in Public Companies.

–NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical in vivo and in vitro studies– –Immunoglobulin-like transcript 3 (ILT3) is a highly specific marker of acute myeloid leukemia (AML) with monocytic differentiation and is not expressed on non-monocytic blood cells or hematopoietic progenitor cells, making ILT3 a potentially promising target for monocytic AML– –AML with monocytic differentiation accounts for 25–30% of all AML cases and has a particularly poor prognosis, with a worse overall survival rate than other forms of AML and a greater risk of extramedullary relapse– SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals,...

Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Written by Customer Service on December 13, 2022. Posted in Public Companies.

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal off-tumor toxicity Phase I clinical trial evaluating safety and dose of MP0533 in patients with Relapsed/Refractory AML and high-risk MDS to start imminentlyZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, presented today new preclinical data showing its DARPin T-cell engager MP0533 can induce preferential killing of cells expressing two or three tumor-associated antigens (TAAs) compared to cells expressing a single TAA. The data was...

Savaria President and CEO Intends to Distribute Securities

Written by Customer Service on December 13, 2022. Posted in Public Companies.

LAVAL, Québec, Dec. 12, 2022 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, announces today that Mr. Marcel Bourassa, President and CEO of Savaria, has filed a notice of intention to distribute securities in connection with his proposed sale of up to 1,700,000 common shares of Savaria (representing up to 2.64% of the issued and outstanding common shares). The common shares are expected to be sold through the facilities of the Toronto Stock Exchange and may also be sold or transferred privately. The common shares are proposed to be sold by Mr. Marcel Bourassa for personal reasons, for family estate planning purposes and in support of philanthropic endeavors. As he holds some of his common shares in Savaria through various holding companies, this proposed sale of shares...

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology

Written by Customer Service on December 13, 2022. Posted in Public Companies.

– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids – – Pegozafermin has the potential to be a best-in-class treatment for individuals with NASH, a patient population in need of effective and well-tolerated therapies – SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that data from cohorts 1-6 in the the Phase 1b/2a proof-of-concept study evaluating pegozafermin for the treatment of nonalcoholic steatohepatitis (NASH) was published online in The...

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

Written by Customer Service on December 12, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the “Contract”) with Brio Financial Group (“Brio”) to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provides outsourced financial management and financial reporting support to small and middle market entities. Currently, the team provides consulting...

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

Written by Customer Service on December 12, 2022. Posted in Public Companies.

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resistance to both covalent and non-covalent BTK inhibitors remain susceptible to degradation by NX-2127 Nurix will host a Key Opinion Leader (KOL) webcast event at 9:30 pm ET today to review data presented at ASH and progress in its degrader portfolio SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today presented additional positive clinical data from its Phase 1 clinical trial of NX-2127 in two oral sessions by...

Northwestern Enterprises Ltd. Acquires Common Shares of Aura Minerals Inc.

Written by Customer Service on December 12, 2022. Posted in Mergers And Acquisitions.

ROAD TOWN, British Virgin Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) — Northwestern Enterprises Ltd. (“Northwestern”), a company beneficially owned by Paulo Carlos de Brito, announces that it has acquired 280,000 common shares (“Aura Shares”) of Aura Minerals Inc. (“Aura”) in normal course transactions on the Toronto Stock Exchange with the result that Northwestern owns or has control or direction over an aggregate of 38,136,105 Aura Shares, representing approximately 53.0671% of the issued and outstanding Aura Shares. The 280,000 Aura Shares were purchased at an average of $7.70 per Aura Share, for an aggregate of $2,156.000. The acquisition of the Aura Shares was completed as part of Northwestern’s ongoing review of its investment holdings, and to permit it to increase its ownership position in Aura. Northwestern intends to evaluate...

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals